For Healthcare Professionals
Product and educational resources
IBSA's COMMITMENT
Luke Ferreira : IBSA’s International Infiltration Lab Malta
22-24th March 2024 I was invited to attend the IBSA International Infiltration Lab in Malta 22nd -24th March. I found the weekend thoroughly enjoyable and clinically very informative. The course leads brought expertise and a genuine desire to teach and facilitate learning from around Europe from MSK, Orthopaedic, Rheumatology and Ultrasonography backgrounds. IBSA organised all…
Read More
Michael McMahon : IBSA’s International Infiltration Lab Malta
22-24th March 2024 I really enjoyed the IBSA International Infiltration Lab in Malta. It was very well-organised from start to finish, with transfers, hotel and logistics etc. The lectures were very interesting hearing about the composition and manufacture of Sinovial and its effects. The course leaders were very engaging and knowledgeable, and went out of the…
Read More
Charli Robertson : IBSA’s International Infiltration Lab Malta
21st March Thank you for inviting me on this insightful live observation of ultrasound guided joint injection with the IBSA International Academy group. As a physiotherapist specialising in performance sport in the UK, joint injury and degeneration impacts a number of athletes in my care, particularly those later in their career and/or with a history of…
Read MoreBLOG POSTS
Growing burden of Osteoarthritis in the United Kingdom (UK)
Osteoarthritis (OA) is the most common form of arthritis in adults, which is characterised by persistent pain, loss of mobility and reduced quality of life. In the UK alone, there are an estimated 5.4 million people living with knee OA and 3.2 million people with hip OA. As the population ages, coupled with rising obesity…
Read MoreThe treatment options for managing Osteoarthritis (OA)
Patients in the NHS may manage OA symptoms in the early stages conservatively with analgesic medication, steroid injections, exercise, physiotherapy and weight reduction. There is an imperative to reduce opioid use for persistent pain, due to addiction risk, side effects and long-term increased sensitivity to pain. There is growing evidence to refute the usefulness of…
Read MoreIBSA’S Hyaluronic Acids
In 2016 IBSA recognised the limitation of linear and cross-linked technology in producing HA. Their scientists researched and created a patented technology to produce a novel molecular structure for HA consisting of a hybrid cooperative complex, combining both high and low molecular weight in a single injection (Sinovial HL®), signifying an innovative step forward in…
Read MorePRODUCTS
IBSA specialises in research and development, production and marketing of hyaluronic acid-based products.
